H
uman adipose-derived stem cells are multipotent autologous mesenchymal stem cells. These multipotent cells are recognized as a potential regenerative tool that may be beneficial in a wide variety of medical therapies in reconstructive surgery and in a multitude of other medical disciplines. 1 The clinical potential of adiposederived stem cells has proven to be a source of considerable enthusiasm and scientific curiosity in academic circles and more recently commercially as an emerging business opportunity. Clinicians and patients alike have high expectations that adipose-derived stem cells may well be the answer to curing many recalcitrant diseases or reconstructing anatomical defects.
As clinical applications using adipose-derived stem cells have been increasingly reported, there has been growing concern, generating criticism that clinical practices using adipose-derived stem cells have not been substantiated by rigorous scientific evidence. To address some of these concerns, in May of 2011, the American Society of Plastic Surgeons and the American Society for Aesthetic Plastic Surgery published a joint position statement concerning stem cells. 2 This document reported that the scientific evidence was very limited in terms of assessing the safety and efficacy of stem cell therapies in aesthetic medicine. This statement included the recommendations of the Task Force, which stated in general terms that stem cell procedures should be performed in compliance with U.S. Food and Drug Administration regulatory guidelines, and that the preparation and processing of adipose-derived stem cells should be conducted in accordance with current good manufacturing practice guidelines. 3 The aim of this report is to collate the results of published reports that specifically look at the basic science behind adipose-derived stem cell therapies from different units across the globe. In so doing, we hope to provide a comprehensive review of the current literature across all medical disciplines that describe the clinical uses of adipocyte-derived stem cells in clinical medicine.
ADIPOSE-DERIVED STEM CELLS: DEFINITION, EXTRACTION, AND PROPERTIES
Adipose-derived stem cells were identified as such by Zuck et al. in 2001; these authors defined the stem cell characteristics of adipose-derived stem cells by their ability to differentiate into several mesenchymal lineages. 4 Adipose-derived stem cell extraction from adipose tissue requires a multistep laboratory-based process. The majority of laboratories use collagenases that generate a cell pellet following centrifugation that has been termed the stromal vascular fraction. The stromal vascular fraction consists of multiple cell types, including circulating blood cells, fibroblasts, pericytes, endothelial cells, and adipose-derived stem cells. 5 Adipose-derived stem cells can be isolated from the stromal vascular fraction through culturing on plastic as, unlike the other cell types in the stromal vascular fraction, they adhere to plastic. In addition, they can be identified by means of fluorescence-activated cell sorting, as they have several specific surface markers: CD73 ϩ , CD90 ϩ , CD105
ϩ , CD45 -, CD34 -, CD14 or CD11b, CD79 -or CD19 -, and HLA-DR 6 ( Fig. 1 ).
Adipose-derived stem cells possess the ability to readily be expanded in vitro and the capacity to undergo adipogenic, osteogenic, chondrogenic, and myogenic (cardiomyocyte and skeletal myocyte) differentiation. 4 Neurogenic differentiation potential has also been described in vitro, [7] [8] [9] [10] as has pancreatic endocrine phenotype expressing insulin, 11 hepatic, 12, 13 and endothelial differentiation (Fig. 2 ). 14 The metabolic properties of adipose-derived stem cells (angiogenic, antioxidative, immunotolerance) have been demonstrated in bench experiments and increasingly in preclinical models. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] First, adipose-derived stem cells secrete a favorable cytokine profile that is angiogenic, immunosuppressive, and antioxidative. 25 The cytokine profile of adipose-derived stem cells contains large amounts of vascular endothelial growth factor, transforming growth factor-␤, hepatocyte growth factor, plateletderived growth factor, placental growth factor, and basic fibroblast growth factor, which explains their impressive angiogenic capacity and their ability to induce tissue neovascularization. 16 Second, adipose-derived stem cells have been shown to be immune-privileged because of a lack of human leukocyte antigen-DR expression and the suppression of the proliferation of activated allogenic lymphocytes. 26, 27 Adipose-derived stem cells have also been shown to inhibit the production of inflammatory cytokines and to stimulate the production of antiinflammatory cytokines. 
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The immunomodulatory properties of adipose-derived stem cells have been demonstrated in vitro and in vivo. 30 -33 The correlations of the data sets derived from these models are currently being tested in several clinical studies to be reviewed later.
There is still concern regarding adipose-derived stem cell use in a clinical setting. In a recent review, published in March of 2011, Locke et al. emphasized that the literature revealed considerable uncertainty about the true clinical potential of adipose-derived stem cells. 34 According to these authors, first, the differentiation of adipose-derived stem cells into cell lineages in vivo has not been conclusively demonstrated in many studies because of the use of rather simplistic approaches to the confirmation of differentiation. An example of this would be neurogenic differentiation of adipose-derived stem cells. 35 Second, adipose-derived stem cells prepared from human liposuction from different studies differ in purity and molecular phenotype, with many studies using cell preparations that are likely to contain heterogeneous populations of cells, making it uncertain whether adipose-derived stem cells themselves are responsible for effects observed. They concluded that the full clinical potential of adipose-derived stem cells awaits much deeper investigation of their fundamental biology.
The immunologic and angiogenic properties of adipose-derived stem cells raise the question of the relation of these cells with promoting cancer. Several contradictory studies have been published, with some reports demonstrating that adipose-derived stem cells could promote tumor growth. 36 -41 Conversely, others report that adipose-derived stem cells could have a tumor-suppressive effect. [42] [43] [44] The answer to that question remains unknown, and further studies are necessary to determine the effect of adipose-derived stem cells on tumor formation.
Lastly, the production of a clinically acceptable grade of adipose-derived stem cells requires careful assessment of the risks and benefits. It is important to identify and control all possible molecules that may affect the efficacy of the adiposederived stem cell preparation, which should be performed in accordance with current good manufacturing practice guidelines.
U.S. FOOD AND DRUG ADMINISTRATION REGULATIONS, GOOD MANUFACTURING PRACTICE, AND THE EUROPEAN POSITION
The U.S. Food and Drug Administration has developed a regulatory framework based on three areas 45 47 In Europe, adipose-derived stem cells are considered Advanced Therapy Medicinal Products, as defined by the European Regulation (European Commission) 1394/2007, which contains rules for "authorization, supervision, and technical requirements regarding the summary of products characteristics, labeling, and the package leaflet of Advanced Therapy Medicinal Products that are prepared following industrials methods and in academic institutions." 47 This regulation refers to the European good manufacturing process rules. 48 The process of converting research-based protocols using adipose-derived stem cells into a safe manufacturing process that is good manufacturing process-compliant requires protocols that have had careful consideration of all the risks and benefits for the patient end user. In particular, Sensebé et al. stated that the following parameters should be considered: sources and collection methods, cell seeding, proliferation rate, and culture medium. They went on to identify steps for quality control that must be carried out at cell harvest and during the various phases of adiposederived stem cell production. 49 Furthermore, automated devices for separating adipose stem cells are regulated as class III medical devices by the U.S. Food and Drug Administration. 50 Currently, no such device is approved for human use in the United States. These are considered as research tools and should only be used under and approved by the Product Development Protocol. 51 Because of the rigors of safe, reproducible, quality-controlled adipose-derived stem cell production as required by the U.S. Food and Drug Administration, it is easy to see why the use of adipose-derived stem cells in clinical trials or for clinical applications is still very rare in the United States.
CLINICAL APPLICATIONS OF ADIPOSE-DERIVED STEM CELLS: PUBLISHED LITERATURE AND ONGOING CLINICAL TRIALS
This section reports the different publications found concerning the clinical use of adipose-derived stem cells and also the clinical trials currently being performed around the world. These appliPlastic and Reconstructive Surgery • June 2012 cations were organized into two areas: plastic surgery and the other medical specialties.
In a review published in June of 2011, Lindroos et al. found 18 clinical trials concerning the use of adipose-derived stem cells in regenerative medicine. 52 A search performed on www.clinicaltrials.gov with the search term "adipose stem cell therapy," performed in August of 2011, revealed 33 studies based on adipose-derived stem cell therapy, which demonstrates the rapid evolution and expansion of clinical use of adipose-derived stem cells. Five clinical trials were found for the plastic surgery area (Table 1) , and 28 were found in the other specialties (Table 2) . Table 3 represents the location of the clinical trials in the world. Spain and Korea are the two leaders in this area, with 10 studies performed in each country. Only three trials are currently being performed in the United States, which is attributable to the high level of exigency of the U.S. Food and Drug Administration regulations.
PUBLISHED CLINICAL APPLICATIONS AND CLINICAL TRIALS IN PLASTIC SURGERY
Plastic surgery is a field where the clinical use of adipose-derived stem cells is well developed. The cells are usually in the form of autologous stromal vascular fraction cells or noncultured adipose-derived stem cells, with one treatment given in a local immediate administration mainly in combination with fat grafts. Within the literature, adipose-derived stem cells have been used or studied in three main areas: soft-tissue augmentation, wound healing, and tissue engineering.
Published Clinical Applications
Soft-Tissue Augmentation Yoshimura et al. [53] [54] [55] reported several studies using the cell-assisted lipotransfer technique for treatment of facial lipoatrophy, cosmetic breast augmentation, or immediate breast augmentation after breast implant removal (Table 4) . [53] [54] [55] [56] [57] [58] [59] [60] [61] The principle of this technique is to enrich the fat grafting material with stromal vascular fraction. In their breast augmentation study, the authors stated that "augmentation effects were apparently increased with the cell-assisted lipotransfer technique compared with patients who underwent traditional lipoinjection," but no comparative control group was used. 54 In their facial lipoatrophy study, one half of the face was treated with cellassisted lipotransfer and the contralateral side was treated by the traditional lipoinjection Volume 129, Number 6 • Human Adipose-Derived Stem Cells Volume 129, Number 6 • Human Adipose-Derived Stem Cells technique. 55 They reported that transplanted adipose tissue was absorbed faster in the non-cellassisted lipotransfer group compared with the cellassisted lipotransfer-treated group over the long term.
In 2011, two additional noncontrolled trials using the cell-assisted lipotransfer strategy were published. In the first, by Tiryaki et al., the authors observed not only a better graft take but also a subjective gradual regeneration of the skin overlying the graft, in 29 patients undergoing softtissue augmentation. 56 They stated that the technique was particularly successful in secondary cases that had been previously treated with fat grafting without significant improvement. The second study, by Kamakura and Ito, reported 20 cases of breast augmentation using the cell-assisted lipotransfer technique and concluded that this technique is a safe and effective method for breast augmentation. 57 In 2011, Kim et al. published the result of a clinical trial involving 31 patients treated with adipose-derived stem cells that were differentiated into mature adipocytes for facial depressed scars, but again with no comparative control group. 58 Adipose-derived stem cells were isolated from adipose tissue harvested by liposuction, expanded in culture, and differentiated into mature adipocytes, which they termed "AdipoCell" (Table 1) . AdipoCell preparations were injected subcutaneously into the depressed scars, and the volume of each scar was measured using three-dimensional scans. They observed 74.6 percent mean recovery in volume when the received dose of AdipoCell was equivalent to three-eighths of the cell volume of the defect and that the volume was stable at 1 year after treatment. They concluded that this technique represented a new safe and effective therapy for soft-tissue augmentation.
Wound Healing
In 2007, Rigotti et al. published a study concerning 20 patients undergoing therapy for side effects of radiation treatment with severe symptoms and irreversible functional damage from radiation wounds. 59 Fat was harvested by manual liposuction and centrifuged, and the purified lipoaspirate was injected into the irradiated treatment site. An improvement of tissue wound healing was observed, and the authors postulated that the lipoaspirate was rich in native adipose-derived stem cells that contributed to the observed effect.
In 2010, Akita et al. reported on a case of one patient with an intractable wound in the sacrococcygeal region secondary to radiation therapy. 60 The wound healed with a combination treatment of a human recombinant basic fibroblast growth factor, artificial skin substitute, and autologous adipose-derived stem cells, some of which were injected into the wound. However, the true effect 61 The authors observed no new adipose tissue formation, and concluded that this was attributable to a deficient angiogenic response to sustain the long-term adipose-derived stem cell viability and no adverse effect.
Clinical Trials
Five clinical trials involving adipose-derived stem cell therapies were found, and three studies have been completed (Table 1) . However, not all published results are available. The main focus of these clinical trials was soft-tissue augmentation.
A phase I study of autologous adipose-derived stem cell transplantation is currently ongoing in Brazil in patients with lipodystrophy. Lipoinjection enriched with adipose-derived stem cells is being performed, and five subjects are enrolled. The primary outcome measure is the volume improvement of the transplanted area.
A phase II study in Korea is examining the effect of adipose-derived stem cells in Romberg disease, and five subjects are enrolled. The primary outcome measure is the evaluation of the volume change of the fatty layer using three-dimensional image analysis.
Phase II and III studies were studying the safety and efficacy of autologous cultured adipose-derived stem cells in patients with depressed scars, and 36 subjects were enrolled to receive cultured autologous adipose-derived stem cells that had been differentiated into mature adipocytes (AdipoCell). The primary outcome measures were to assess scar improvement and safety.
A phase IV postmarket study, RESTORE-2, examined autologous fat enhanced with adipose-derived stem cells for reconstructing breast deformities after lumpectomy. Primary outcome measures were patient and physician satisfaction assessments with functional and cosmetic improvement in overall breast deformity correction at 12 months. This study was conducted in Belgium, Italy, Spain, and the United Kingdom.
In the United States, a phase II proof-of-concept study by Antria is currently recruiting to demonstrate the effectiveness of their digestive enzymes for human use (Antria Cell Preparation Process) for extraction of stromal vascular fraction from adipose tissue.
In summary, the patients treated with adiposederived stem cells in plastic surgery represent, thus far, 174 published cases to our knowledge (Table  4) . One hundred twenty-one patients are or have been enrolled in clinical trials (Table 1) . In all published cases, no major adverse effects have been reported. The results were encouraging in soft-tissue augmentation and in wound healing.
PUBLISHED CLINICAL APPLICATIONS AND CLINICAL TRIALS IN OTHER SPECIALTIES Published Clinical Applications
To date, a wide variety of specialties have used adipose-derived stem cell therapy, but the number of patients who have been treated with adiposederived stem cells is still very limited and represents 115 patients around the world (Table 5) . Most of the publications retrieved are case reports and noncontrolled studies of level 4/5 evidence, and results, although encouraging, have not been subject to the scientific rigors of a controlled trial.
From 2006 to 2011, Fang et al. used allogenic adipose-derived stem cells in the treatment of hematologic and immunologic disorders: graftversus-host disease, idiopathic thrombocytopenic purpura, or pure red cell aplasia. [62] [63] [64] [65] [66] [67] In each case, patients received intravenous infusion of allogenic adipose-derived stem cells isolated from adipose tissue of healthy donors. No adverse effects after the treatment were observed, and significant improvements were documented with recovery from graft-versus-host disease and pure red cell aplasia, and remission in the idiopathic thrombocytopenic purpura cases. These results provide evidence that the immunomodulatory effects of adipose-derived stem cells may be used in treating immunologic disorders.
In diabetes mellitus type 1, in 2008, Trivedi et al. treated five patients with allogenic adipose-derived stem cells cultured and differentiated into insulin-making mesenchymal stem cells transfused mixed with unfractionated autologous cultures of bone marrow. 68 No adverse effects were reported, all subjects were reported to be healthier and gaining weight, and biological markers were also improved. The authors concluded that adipose-derived stem cell therapy may be a solution for the treatment of insulinopenic patients.
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In 2010, Vanikar et al. reported the results obtained on 11 diabetic patients using the same treatment. 69 Again, no adverse events were reported and a gradual decrease in insulin requirements was noted. The authors concluded that easy and repeatable access to adipose tissue provided a clear advantage over isolation of mesenchymal stem cells from bone marrow for the treatment of diabetes mellitus by stem cell therapy.
From 2003 to 2010, García-Olmo et al. published several articles concerning the treatment of complex perianal or enterocutaneous fistulas, performing phase I and II clinical trials. These included patients with digestive fistulas associated or not with Crohn disease using autologous adiposederived stem cells isolated mixed with fibrin glue and injected into the fistulous tract. 70 -75 In all the studies, no adverse effects were reported and a significant healing rate was observed in patients who received adipose-derived stem cells (71 percent of healing compared with 16 percent). They concluded that adipose-derived stem cell therapy associated with fibrin glue is a safe and effective method of treating complex perianal fistula.
Rheumatoid arthritis treatments were examined in a case report in 2010 by Ichim et al. of a 67-year-old woman. 76 The patient was treated by intravenous infusions of autologous stromal vascular fraction cells isolated from a liposuction procedure. The authors observed no side effects, and the patient reported a considerable resolution of her pain joint and stiffness, with a decrease in rheumatoid factor. They concluded that adiposederived stem cell therapy may be a treatment for rheumatoid arthritis and postulated that this was because of the immune-tolerance induced by adipose-derived stem cells.
In 2009, Riordan et al. reported the treatment of three multiple sclerosis patients with intravenous infusions of autologous stromal vascular fraction cells with multiple intrathecal and intravenous infusions of allogenic CD34 and mesenchymal stem cells within a 10-day period. 77 No adverse effects were documented, and by 3 months, all patients reported significant improvement of their symptoms. The authors concluded that further clinical evaluation of autologous stromal vascular fraction cells is warranted in autoimmune conditions.
In 2008, Alvarez et al. reported the case of a 67-year-old man suffering from lung cancer complicated with tracheomediastinal fistula and treated by autologous adipose-derived stem cells mixed with fibrin glue, injected into the fistula during bronchoscopy. 78 The patient's recovery was uneventful, and epithelialization of the fistula was observed after 3 months. One year after treatment, the fistula was closed, and 2 years after stem cell therapy, the patient was in complete remission.
There are four published case reports regarding bone tissue repair. In 2004, Lendeckel et al. published the case of a 7-year-old girl suffering from widespread calvarial defects after severe head injury. 79 The patient was treated with a combination of cancellous bone grafts from the 80 The patient's reconstruction was performed using a preformed titanium cage filled with autologous cultured adipose-derived stem cells, combined with synthetic bioresorbable beta-tricalcium phosphate granules. No adverse effects were reported, and bone regeneration was observed by biopsy. They concluded that the presence of adipose-derived stem cells may have enhanced the osteogenic and angiogenic conditions of the construct in vivo.
In 2010, Taylor published the case of a 14-year-old boy suffering from Treacher Collins syndrome whose severe biorbitozygomatic hypoplasia was treated with tissue-engineered bone using a combination of sculpted bone allograft, bone morphogenetic protein-2, periosteal grafts, and autologous fresh adipose-derived stem cells. 81 At 4 months, computed tomographic scanning showed complete bone reconstruction of the bilateral zygomas, and 6 months after surgery, a biopsy specimen showed lamellar bone with small marrow elements. The authors concluded that that type of engineered construct may provide an alternative method to both osteocutaneous free flaps and large structural allografts.
In 2011, Pak reported two cases of patients suffering from osteonecrosis of the femoral head and two cases of patients suffering from knee osteoarthritis. 82 All the patients were treated by a combination of percutaneously injected autologous adipose-derived stem cells, hyaluronic acid, platelet-rich plasma, and calcium chloride. At 3 months, in all cases, pain and mobilization were improved. Magnetic resonance imaging scans showed a significant filling of bone defects, with a possibility of bone matrix formation at the site of osteonecrosis and a significant increase in the thickness and the height of meniscus cartilage. The authors conclude that these good results can be explained either by a direct differentiation of adipose-derived stem cells or by the trophic effects of adipose-derived stem cells on existing tissues.
In 2010, Yamamoto et al. reported two cases of patients with stress urinary incontinence, which is a distressing complication of radical prostatectomy, who were treated with autologous adiposederived stem cells isolated using the Celution System (Cytori Therapeutics, Inc., San Diego, Calif.) and injected (mixed with adipose tissue) in the external urethral sphincter under endoscopic vision. 83 The authors observed no adverse effects. Urinary incontinence improved progressively after 2 weeks, up to 12 weeks. Sphincter function of the urethra was improved in both cases, and magnetic resonance imaging showed a bulking effect at the site of injection. They concluded that adipose-derived stem cell therapy was a safe and feasible treatment for stress urinary incontinence.
In 2011, Ra et al. published a study of eight patients suffering from spinal cord injury who were treated with intravenous infusions of autologous adipose-derived stem cells. 84 The authors observed no serious adverse effects. At 12 weeks, motor function was improved in four patients. The authors concluded that they could not determine the efficacy of adipose-derived stem cell therapy because of their small patient group and the short follow-up period.
In summary, these studies reported no major adverse effects after treatment by adipose-derived stem cells, and the results were promising in the 115 published cases ( Table 5 ). The characteristics of adipose-derived stem cell therapy in these specialties were as follows:
1. Adipose-derived stem cells used were allogenic or autologous; stromal vascular fraction cells or cultured adipose-derived stem cells. 2. In some cases, additive treatments (e.g., bone marrow, growth factor, fibrin glue) were used. 3. The administration doses were variable, as was the number of adipose-derived stem cells per dose. 4. Adipose-derived stem cells were administered systemically (intravenous infusion) or locally (intralesional injection).
Clinical Trials
Twenty-eight clinical trials using adipose and/or adipose-derived stem cells were listed; eight of these studies have been completed. The studies are separated by topic, clinical phase, primary site location, and study status ( Table 2 ). The trials have been organized into five categories: digestive disease, autoimmune disease, cardiovascular disease, skeletal regeneration, and neurologic disorder.
In summary, adipose-derived stem cells have been used in a wide variety of ways:
Volume 129, Number 6 • Human Adipose-Derived Stem Cells Some clinical trials were based on immunologic or angiogenic properties of adipose-derived stem cells, for example, trials concerning the treatment of autoimmune diseases, limb ischemia, or diabetic wounds in the lower extremity. Other trials use differentiation of adipose-derived stem cells into several lineages to study their use in the treatment of degenerative arthritis, cardiac insufficiency, or spinal cord injury. Of the eight trials already completed, to our knowledge, only two have published results, 73, 84 which are described in the previous section, and in both of those, there have been no adverse effects, and encouraging outcomes were reported.
CONCLUSIONS
The important role of adipose-derived stem cells in regenerative medicine is now coming under closer scrutiny. This is because adipose-derived stem cells are easily available and demonstrate several interesting properties, and evidence from preclinical studies suggests potential clinical promise in many medical disciplines. From this review, it can be noted that there is no standard protocol for adipose-derived stem cell use or clinical application in terms of type of cells used (stromal vascular fraction cells or cultured and purified adipose-derived stem cells). In addition, there is no consensus on the number of cells required per dose or treatment or how many treatments are required before an improved clinical outcome can be documented. Consequently, further basic science experimental studies with standardized protocols and larger randomized controlled trials need to be performed to ensure the safety and efficacy of adipose-derived stem cells in accordance with U.S. Food and Drug Administration guidelines. This review aims to make plastic surgeons aware, because of their unique privileged access to adipose tissue, of the development of adipose-derived stem cell therapies not only within plastic surgery but also, as evidenced by this review, the more frequent use in other medical specialties.
